Ingram Biosciences

Ingram Biosciences is a private, pre-clinical stage biotechnology company headquartered in Wayne, Pennsylvania, focused on the discovery and development of novel small molecule therapeutics. The company primarily focuses on the inhibition of Salt-Inducible Kinases (SIK1, SIK2, and SIK3), which are key regulators in oncogenic pathways and immune response modulation. Founded by Dr. Benjamin Ingram, a medicinal chemist with significant experience at Merck and Janssen, the firm utilizes a target-driven approach to optimize lead compounds for the treatment of cancer and autoimmune disorders. Ingram Biosciences holds a proprietary portfolio of patents relating to pyrazolo[1,5-a]pyrimidine derivatives and other kinase inhibitors. The company operates as a specialized R&D entity, prioritizing medicinal chemistry and lead optimization to advance its therapeutic candidates. Its current efforts are focused on identifying potent and selective inhibitors for high-value biological targets in the oncology space.